Cargando…
The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment
Nowadays, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become the main subject of the scientific medical world and all World Organizations, causing millions of deaths worldwide. In this review, we have highlighted the context of the Coronavirus disease 2019 (COVID-19) p...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875987/ https://www.ncbi.nlm.nih.gov/pubmed/35208584 http://dx.doi.org/10.3390/medicina58020261 |
_version_ | 1784658061898547200 |
---|---|
author | Tanase, Alina Manea, Aniko Scurtu, Alexandra Denisa Bratu, Lavinia Melania Chioran, Doina Dolghi, Alina Alexoi, Iren AAbed, Hazzaa Lazureanu, Voichita Dehelean, Cristina Adriana |
author_facet | Tanase, Alina Manea, Aniko Scurtu, Alexandra Denisa Bratu, Lavinia Melania Chioran, Doina Dolghi, Alina Alexoi, Iren AAbed, Hazzaa Lazureanu, Voichita Dehelean, Cristina Adriana |
author_sort | Tanase, Alina |
collection | PubMed |
description | Nowadays, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become the main subject of the scientific medical world and all World Organizations, causing millions of deaths worldwide. In this review, we have highlighted the context of the Coronavirus disease 2019 (COVID-19) pandemic, how the virus spreads, the symptoms and complications that may occur, and, especially, the drug treatment of viral infection, with emphasis on monoclonal antibodies. While well-known strains such as Alpha, Beta, Gamma, and, especially, Delta have shown an accelerated transmission among the population, the new Omicron variant (discovered on 24 November 2021) indicates more significant infectiousness and the poor efficacy of monoclonal antibody therapy due to mutations on the spike protein receptor-binding domain. With these discoveries, the experiments began, the first being in silico and in vitro, but these are not enough, and in vivo experiments are needed to see exactly the cause of neutralization of the action of these drugs. Following the documentation of the latest medical and scientific research, it has been concluded that there are many chemical molecules that have the potential to treat SARS-CoV-2 infection, but more detailed clinical trials are needed for their use in therapy. In addition, it is important to consider the structure of the viral strain in the administration of treatment. |
format | Online Article Text |
id | pubmed-8875987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88759872022-02-26 The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment Tanase, Alina Manea, Aniko Scurtu, Alexandra Denisa Bratu, Lavinia Melania Chioran, Doina Dolghi, Alina Alexoi, Iren AAbed, Hazzaa Lazureanu, Voichita Dehelean, Cristina Adriana Medicina (Kaunas) Review Nowadays, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become the main subject of the scientific medical world and all World Organizations, causing millions of deaths worldwide. In this review, we have highlighted the context of the Coronavirus disease 2019 (COVID-19) pandemic, how the virus spreads, the symptoms and complications that may occur, and, especially, the drug treatment of viral infection, with emphasis on monoclonal antibodies. While well-known strains such as Alpha, Beta, Gamma, and, especially, Delta have shown an accelerated transmission among the population, the new Omicron variant (discovered on 24 November 2021) indicates more significant infectiousness and the poor efficacy of monoclonal antibody therapy due to mutations on the spike protein receptor-binding domain. With these discoveries, the experiments began, the first being in silico and in vitro, but these are not enough, and in vivo experiments are needed to see exactly the cause of neutralization of the action of these drugs. Following the documentation of the latest medical and scientific research, it has been concluded that there are many chemical molecules that have the potential to treat SARS-CoV-2 infection, but more detailed clinical trials are needed for their use in therapy. In addition, it is important to consider the structure of the viral strain in the administration of treatment. MDPI 2022-02-10 /pmc/articles/PMC8875987/ /pubmed/35208584 http://dx.doi.org/10.3390/medicina58020261 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tanase, Alina Manea, Aniko Scurtu, Alexandra Denisa Bratu, Lavinia Melania Chioran, Doina Dolghi, Alina Alexoi, Iren AAbed, Hazzaa Lazureanu, Voichita Dehelean, Cristina Adriana The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment |
title | The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment |
title_full | The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment |
title_fullStr | The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment |
title_full_unstemmed | The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment |
title_short | The “Invisible Enemy” SARS-CoV-2: Viral Spread and Drug Treatment |
title_sort | “invisible enemy” sars-cov-2: viral spread and drug treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875987/ https://www.ncbi.nlm.nih.gov/pubmed/35208584 http://dx.doi.org/10.3390/medicina58020261 |
work_keys_str_mv | AT tanasealina theinvisibleenemysarscov2viralspreadanddrugtreatment AT maneaaniko theinvisibleenemysarscov2viralspreadanddrugtreatment AT scurtualexandradenisa theinvisibleenemysarscov2viralspreadanddrugtreatment AT bratulaviniamelania theinvisibleenemysarscov2viralspreadanddrugtreatment AT chiorandoina theinvisibleenemysarscov2viralspreadanddrugtreatment AT dolghialina theinvisibleenemysarscov2viralspreadanddrugtreatment AT alexoiiren theinvisibleenemysarscov2viralspreadanddrugtreatment AT aabedhazzaa theinvisibleenemysarscov2viralspreadanddrugtreatment AT lazureanuvoichita theinvisibleenemysarscov2viralspreadanddrugtreatment AT deheleancristinaadriana theinvisibleenemysarscov2viralspreadanddrugtreatment AT tanasealina invisibleenemysarscov2viralspreadanddrugtreatment AT maneaaniko invisibleenemysarscov2viralspreadanddrugtreatment AT scurtualexandradenisa invisibleenemysarscov2viralspreadanddrugtreatment AT bratulaviniamelania invisibleenemysarscov2viralspreadanddrugtreatment AT chiorandoina invisibleenemysarscov2viralspreadanddrugtreatment AT dolghialina invisibleenemysarscov2viralspreadanddrugtreatment AT alexoiiren invisibleenemysarscov2viralspreadanddrugtreatment AT aabedhazzaa invisibleenemysarscov2viralspreadanddrugtreatment AT lazureanuvoichita invisibleenemysarscov2viralspreadanddrugtreatment AT deheleancristinaadriana invisibleenemysarscov2viralspreadanddrugtreatment |